Event Brief
Aug 19, 2026 at 1:06 PM ET
mRNA drug with immunotherapy prevents melanoma recurrence
By The BriefBrief
A clinical trial of more than 1,100 patients found an experimental mRNA drug, intismeran autogene, delivered with an immunotherapy treatment could prevent melanoma from returning. The approach, using mRNA technology similar to Moderna and Pfizer’s Covid-19 vaccines, also prevented the cancer from spreading to other organs.
WHO: Merck and Moderna
WHAT: Merck and Moderna reported that an experimental mRNA melanoma drug prevented melanoma recurrence in a large clinical trial.
WHEN: Reported Aug 18, 2026 at 8:00 PM ET
WHERE: Australia
WHY: The trial results showed the experimental treatment could prevent melanoma from returning and spreading to other organs.
Reporting from 1 identified publisher for this event.
View all 1 publishers
Publishers represented across this event arc
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
South Africa consumer inflation eases in July
South Africa
Aug 19, 2026 at 1:06 PM ET
Sacked Ukraine defence minister calls for presidential poll
Ukraine
Aug 19, 2026 at 1:06 PM ET
Analyst says US is stymied by missile shortages vs Iran
Us
Aug 19, 2026 at 1:04 PM ET
U.S.-South Korea Ulchi drills end Aug. 21 instead of Aug. 27
Ulchi Freedom Shield
Aug 19, 2026 at 1:04 PM ET
